Search

pSivida directors take up entitlements under rights issue

Directors of Perth headquartered global bio-nanotech company pSivida Ltd have confirmed that they will be taking up rights to subscribe for pSivida shares under their respective individual eligible entitlements to raise approximately $29 million.

Capital raised from this rights issue will primarily fund the phase III clinical trials of Medidur for the treatment of Diabetic Macular Edema, and phase IIa clinical trials of our lead BioSilicon product, BrachySil which is being developed for the treatment of inoperable pancreatic cancer.

The rights issue is on a non-renounceable 1 for 8 basis to raise approximately $29 million at 60 cents per ordinary share, and has an incorporated top up facility whereby eligible shareholders may apply for additional new ordinary shares in excess of their entitlement at the same price.

The rights issue is not underwritten. The record date for the rights issue was 22 May 2006.

pSivida also announced the Regulatory Agency in the U.K. (The Medicines and Healthcare Products Regulatory Agency) has granted approval to proceed with the first human study of its BrachySil product in pancreatic cancer through a phase IIa clinical trial.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Register for free

Sign up here for free access to 8 articles per month + twice daily business email alerts.

CAPTCHA
Thanks! This question prevents spammers...
Image CAPTCHA
Enter the characters shown in the image.

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

BN30 Index

Index = 100 as of 4 Jan 2016
Source: Morningstar

Total Shareholder Return as at 31/08/16

1 year TSR5 year TSR
112thFortescue Metals Group162%-2%
316thSouth3226%0%
534thWoodside Petroleum-8%1%
543rdIluka Resources-9%-14%
718thAtlas Iron-58%-68%
777 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

20/09/16
$0 Issued
07/09/16
$0 Other
07/09/16
$0 Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

1st-Fortescue Metals Group$9,806.1m
2nd↑South32$8,262.9m
3rd-Woodside Petroleum$6,935.4m
4th↑Iluka Resources$884.1m
5th↑Atlas Iron$803.7m
526 listed resources companies ranked by revenue.
Source: Morningstar

Remuneration from Fortescue Metals Group

3rdNev Power$5.992m
12thStephen Pearce$2.551m
25thNick Cernotta$1.566m
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer